GSK3844766A + AS01B

GSK3844766A + AS01B is a **combination vaccine candidate** targeting respiratory syncytial virus (RSV) in adults, comprising a **recombinant subunit pre-fusion RSV F protein antigen (RSVPreF3)** and the proprietary **AS01B adjuvant system** (developed by GSK). The **mechanism of action** is to induce a strong immune response—including both humoral (antibody) and cellular (T-cell) components—against the RSV F protein in its pre-fusion conformation, which is highly immunogenic and a key target for neutralizing antibodies. The **AS01B adjuvant**, which contains MPL (monophosphoryl lipid A) and QS-21, is used to enhance the magnitude and durability of the immune response, especially in older adults, who experience immunosenescence (age-related immune decline). The vaccine is being developed principally for the **prevention of moderate-to-severe RSV-related lower respiratory tract disease (LRTD) in adults aged 60 years and above**. It is administered via the **intramuscular route**. GSK is the developer and manufacturer. Clinical data in Phase I/II and III studies have shown that the GSK3844766A + AS01B formulation is well tolerated and immunogenic, with robust increases in RSV-neutralizing antibodies and T-cell responses in older adults[1][3][4][5][7][8].

Brand names

Arexvy

Other names

RSV OA-ADJ-002RSVPreF3 OARSVPreF-3 OARSVPreF 3 OA